Abstract
Highly publicised vaccine scares and recent debates about the risks suggest that public trust in immunisation programmes is fragile. For instance, the recent outbreak of Measles in Wales was the direct result of almost fifteen years of distrust for the MMR vaccine in the UK. This article shows how the latest science on risk communication will help critical actors, especially policy-makers, to build trust when they communicate risks to citizens and patients. The article offers policy advice on risk communication based on the results of three vaccines case studies. Five procedural principles which were developed for the UK government – the so-called “five As” of public risk communication are used to structure the discussion. Conclusions and recommendations suggest ways to move forward and build a two-way proactive risk communication practice.
Keywords: Hepatitis B, HPV, MMR, policy, regulation, risk communication, trust.
Current Drug Safety
Title:Risk Communication of Vaccines: Challenges in the Post-Trust Environment
Volume: 10 Issue: 1
Author(s): Frederic Bouder
Affiliation:
Keywords: Hepatitis B, HPV, MMR, policy, regulation, risk communication, trust.
Abstract: Highly publicised vaccine scares and recent debates about the risks suggest that public trust in immunisation programmes is fragile. For instance, the recent outbreak of Measles in Wales was the direct result of almost fifteen years of distrust for the MMR vaccine in the UK. This article shows how the latest science on risk communication will help critical actors, especially policy-makers, to build trust when they communicate risks to citizens and patients. The article offers policy advice on risk communication based on the results of three vaccines case studies. Five procedural principles which were developed for the UK government – the so-called “five As” of public risk communication are used to structure the discussion. Conclusions and recommendations suggest ways to move forward and build a two-way proactive risk communication practice.
Export Options
About this article
Cite this article as:
Bouder Frederic, Risk Communication of Vaccines: Challenges in the Post-Trust Environment, Current Drug Safety 2015; 10 (1) . https://dx.doi.org/10.2174/157488631001150407103916
DOI https://dx.doi.org/10.2174/157488631001150407103916 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric Sequelae of COVID-19
Current Neuropharmacology Editorial
Current Drug Therapy Recent Gains in Clinical Multiple Sclerosis Research
CNS & Neurological Disorders - Drug Targets Molecularly Imprinted Sol-Gel Materials for Medical Applications
Current Topics in Medicinal Chemistry T Cell-Activated Signaling Pathways and Locally Produced Cytokines as Potential Targets in Celiac Disease
Current Drug Targets Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Cellular and Molecular Effects of Macrolides on Leukocyte Function
Current Pharmaceutical Design Nanotechnology in Dentistry: Drug Delivery Systems for the Control of Biofilm-Dependent Oral Diseases
Current Drug Delivery Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis
Current Pharmaceutical Design A Tale of Two Eras: Mining Big Data from Electronic Health Records to Determine Limb Salvage Rates with Podiatry
Current Diabetes Reviews Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Editorial (Thematic Issue: Nanotechnology for Drug Delivery Applications)
Current Drug Delivery The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Therapeutic Nanotechnology for Bone Infection Treatment – State of the Art
Current Drug Delivery PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets